Sarcopenic obesity: epidemiology, pathogenesis and diagnostic criteria
https://doi.org/10.15829/1728-8800-2023-3576
EDN: OWOAYO
Abstract
Recently, two following demographic trends have been clearly observed in the world: population aging and an increase in the prevalence of obesity. In February 2022, the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) published the first consensus guidelines for the definition and diagnosis of sarcopenic obesity, which characterizes by a combination of excess adipose tissue with a decrease in muscle mass, muscle strength and impaired muscle function. The purpose of this review is to describe the prevalence, the main etiopathogenetic factors of sarcopenic obesity, as well as currently accepted approaches to the diagnosis of this condition.
Supporting agencies: The study was conducted within the framework of the scientific work "Association of sarcopenia with metabolic disorders, chronic inflammation and changes in psychological status in obese patients", performed at the National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation in accordance with the state task of the Ministry of Health of the Russian Federation № 123020600129-8 (2023-2025)
About the Authors
S. A. Berns
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
A. F. Sheptulina
National Medical Research Center for Therapy and Preventive Medicine; A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Moscow
E. M. Mamutova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
A. R. Kiselev
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine; A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Moscow
References
1. Toptas M, Yalcin M, Akkoc İ, et al. The Relation between Sarcopenia and Mortality in Patients at Intensive Care Unit. Biomed Res Int. 2018;12;2018:5263208. doi:10.1155/2018/5263208.
2. Ethgen O, Beaudart C, Buckinx F, et al. The Future Prevalence of Sarcopenia in Europe: A Claim for Public Health Action. Calcif Tissue Int. 2017;100(3):229-34. doi:10.1007/s00223-016-0220-9.
3. Cruz-Jentoft AJ, Bahat G, Bauer J, et al; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. doi:10.1093/ageing/afy169. Erratum in: Age Ageing. 2019;48(4):601.
4. Drapkina OM, Budnevsky AV, Ovsyannikov ES, et al. Sarcopenic obesity: patterns and paradoxes. Profilakticheskaya Meditsina. 2021;24(1):73-8. (In Russ.) doi:10.17116/profmed20212401173.
5. Dikova TS, Zatsepina AY, Fedorinov DS, et al. Sarcopenia, sarcopenic obesity, myosteatosis as factors of poor prognosis in gastrointestinal tract tumors: review. Journal of Modern Oncology. 2021;23(1):141-7. (In Russ.) doi:10.26442/18151434.2021.1.200715.
6. Donini LM, Busetto L, Bischoff SC, et al. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obes Facts. 2022;15:321-35. doi:10.1159/000521241.
7. Pasechnik IN, Zakrevskij AI, Talyzin PA, et al. Sarcopenia: Opinion of an Anesthesiologist-Resuscitator. Kremlin Medicine Journal. 2021;1:82-9. (In Russ.) doi:10.26269/zqkk-j843.
8. Lonnie M, Hooker E, Brunstrom JM, et al. Protein for Life: Review of Optimal Protein Intake, Sustainable Dietary Sources and the Effect on Appetite in Ageing Adults. Nutrients. 2018;10(3):360. doi:10.3390/nu10030360.
9. Purcell SA, Mackenzie M, Barbosa-Silva TG, et al. Prevalence of Sarcopenic Obesity Using Different Definitions and the Relationship with Strength and Physical Performance in the Canadian Longitudinal Study of Aging. Front Physiol. 2021;11:583825. doi:10.3389/fphys.2020.583825.
10. Dupuy C, Lauwers-Cances V, Guyonnet S, et al. Searching for a relevant definition of sarcopenia: results from the cross-sectional EPIDOS study. J Cachexia Sarcopenia Muscle. 2015;6(2):144-54. doi:10.1002/jcsm.12021.
11. Gao Q, Mei F, Shang Y, et al. Global prevalence of sarcopenic obesity in older adults: A systematic review and meta-analysis. Clin Nutr. 2021;40(7):4633-41. doi:10.1016/j.clnu.2021.06.009.
12. Rumyantsev AS, Filinyuk PY, Jakovenko AA, et al. Sarcopenic Obesity in Patients Receiving Treatment with Programmed Hemodialysis. Nephrology (Saint-Petersburg). 2022;26(2):77-84. (In Russ.) doi:10.36485/1561-6274-2022-26-2-77-84.
13. Myasoedova SE, Rubtsova OA, Myasoedova EE. Body Composition and Bone Mineral Density in Women with Rheumatoid Arthritis. The Clinician. 2016;10(3):41-5. (In Russ.) doi:10.17650/1818-8338-2016-10-3-41-45.
14. Misnikova IV, Kovaleva YuA, Klimina NA, et al. Assessment of muscle and fat mass in type 2 diabetes mellitus patients by dual-energy X-ray absorptiometry. Almanac of Clinical Medicine. 2018;46(3):222-32. (In Russ.) doi:10.18786/2072-0505-2018-46-3-222-232.
15. Silva TL, Mulder AP. Sarcopenia and poor muscle quality associated with severe obesity in young adults and middle-aged adults. Clin Nutr ESPEN. 2021;45:299-305. doi:10.1016/j.clnesp.2021.07.031.
16. Wagenaar CA, Dekker LH, Navis GJ. Prevalence of sarcopenic obesity and sarcopenic overweight in the general population: The lifelines cohort study. Clin Nutr. 2021;40(6):4422-9. doi:10.1016/j.clnu.2021.01.005.
17. Zembura M, Matusik P. Sarcopenic Obesity in Children and Adolescents: A Systematic Review. Front Endocrinol (Lausanne). 2022;13:914740. doi:10.3389/fendo.2022.914740.
18. Moreira VG, Perez M, Lourenço RA. Prevalence of sarcopenia and its associated factors: the impact of muscle mass, gait speed, and handgrip strength reference values on reported frequencies. Clinics (Sao Paulo). 2019;74:e477. doi:10.6061/clinics/2019/e477.
19. Santanasto AJ, Miljkovic I, Cvejkus RK, et al. Body Composition Across the Adult Lifespan in African Caribbean Men: The Tobago Longitudinal Study of Aging. J Frailty Aging. 2022;11(1):40-4. doi:10.14283/jfa.2021.47.
20. Pasechnik IN, Berns SA, Boyarintseva VV. Myopathies in the practice of a clinician: a guide for doctors. Moscow.: GEOTAR-Media, 2023, p. 448. (In Russ.) ISBN: 978-5-9704-76-48-2.
21. Wiedmer P, Jung T, Castro JP. Sarcopenia — Molecular mechanisms and open questions. Ageing Res Rev. 2021; 65:101200. doi:10.1016/j.arr.2020.101200.
22. Kurmaev DP, Bulgakova SV, Treneva EV. Sarcopenic obesity — a current problem of modern geriatrics. Russian Journal of Geriatric Medicine. 2022;4(12):228-35. (In Russ.) doi:10.37586/2686-8636-4-2022-228-235.
23. Misnikova IV, Kovaleva YuA, Klimina NA. Sarcopenic obesity. breast cancer. RMJ.2017;1:24-9. (In Russ.)
24. Kirk B, Feehan J, Lombardi G, et al. Muscle, Bone, and Fat Crosstalk: the Biological Role of Myokines, Osteokines, and Adipokines. Curr Osteoporos Rep. 2020;18(4):388-400. doi:10.1007/s11914-020-00599-y.
25. Cheng L, Wang J, Dai H, et al. Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus. Adipocyte. 2021;10(1):48-65. doi:10.1080/21623945.2020.1870060.
26. Grunow JJ, Gan T, Lewald H, et al. Insulin signaling in skeletal muscle during inflammation and/or immobilisation. Intensive Care Med Exp. 2023;11(1):16. doi:10.1186/s40635-023-00503-9.
27. Salminen A, Kaarniranta K, Kauppinen A. Insulin/IGF-1 signaling promotes immunosuppression via the STAT3 pathway: impact on the aging process and agerelated diseases. Inflamm Res. 2021;70(10-12):1043-61. doi:10.1007/s00011-021-01498-3.
28. Goodpaster BH, Bergman BC, Brennan AM, et al. Intermuscular adipose tissue in metabolic disease. Nat Rev Endocrinol. 2023;19(5):285-98. doi:10.1038/s41574-022-00784-2.
29. Kahn D, Macias E, Zarini S, et al. Exploring Visceral and Subcutaneous Adipose Tissue Secretomes in Human Obesity: Implications for Metabolic Disease. Endocrinology. 2022;163(11):bqac140. doi:10.1210/endocr/bqac140.
30. Iwase T, Wang X, Shrimanker TV, et al. Body composition and breast cancer risk and treatment: mechanisms and impact. Breast Cancer Res Treat. 2021;186(2):273-83. doi:10.1007/s10549-020-06092-5.
31. Kobayashi M, Deguchi Y, Nozaki Y, et al. Contribution of PGC-1α to Obesity- and Caloric Restriction-Related Physiological Changes in White Adipose Tissue. Int J Mol Sci. 2021;22(11):6025. doi:10.3390/ijms22116025.
32. Zhu W, Sahar NE, Javaid HMA, et al. Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Competitive Binding with MD2. Cells. 2021;10(12):3306. doi:10.3390/cells10123306.
33. Liu XH, Pan JP, Bauman WA, et al. AdipoRon prevents myostatin-induced upregulation of fatty acid synthesis and downregulation of insulin activity in a mouse hepatocyte line. Physiol Rep. 2019;7(13):e14152. doi:10.14814/phy2.14152.
34. Little HC, Rodriguez S, Lei X, et al. Myonectin deletion promotes adipose fat storage and reduces liver steatosis. FASEB J. 2019;33(7):8666-87. doi:10.1096/fj.201900520R.
35. Uchitomi R, Oyabu M, Kamei Y. Vitamin D and Sarcopenia: Potential of Vitamin D Supplementation in Sarcopenia Prevention and Treatment. Nutrients. 2020;12(10):3189. doi:10.3390/nu12103189.
36. Romeu Montenegro K, Carlessi R, Cruzat V, et al. Effects of vitamin D on primary human skeletal muscle cell proliferation, differentiation, protein synthesis and bioenergetics. J Steroid Biochem Mol Biol. 2019;193:105423. doi:10.1016/j.jsbmb.2019.105423.
37. Bass JJ, Kazi AA, Deane CS, et al. The mechanisms of skeletal muscle atrophy in response to transient knockdown of the vitamin D receptor in vivo. J Physiol. 2021;599(3):963-79. doi:10.1113/JP280652.
38. Bass JJ, Nakhuda A, Deane CS, et al. Overexpression of the vitamin D receptor (VDR) induces skeletal muscle hypertrophy. Mol Metab. 2020;42:101059. doi:10.1016/j.molmet.2020.101059.
39. Ehrampoush E, Mirzay Razzaz J, Arjmand H, et al. The association of vitamin D levels and insulin resistance. Clin Nutr ESPEN. 2021;42:325-32. doi:10.1016/j.clnesp.2021.01.012.
40. Charoenngam N, Holick MF. Immunologic Effects of Vitamin D on Human Health and Disease. Nutrients. 2020;12(7):2097. doi:10.3390/nu12072097.
41. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12(4):249-56. doi:10.1016/j.jamda.2011.01.003.
42. Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69(5):547-58. doi:10.1093/gerona/glu010.
43. Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020;21(3):300-7.e2. doi:10.1016/j.jamda.2019.12.012.
44. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412-23. doi:10.1093/ageing/afq034.
45. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-63.
46. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults–The Evidence Report. National Institutes of Health. Obes Res. 1998;6 Suppl 2:51S-209S. Erratum in: Obes Res. 1998 Nov;6(6):464.
47. Misra A, Vikram NK, Gupta R, et al. Waist circumference cutoff points and action levels for Asian Indians for identification of abdominal obesity. Int J Obes (Lond). 2006;30(1):106-11. doi:10.1038/sj.ijo.0803111.
48. Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98-107. doi:10.1016/j.metabol.2018.10.011.
49. Timofeev YuS, Dzhioeva ON, Drapkina OM. Circulating biological markers of obesity: towards a systems approach. Cardiovascular Therapy and Prevention. 2023;22(4):3551. (In Russ.) doi:10.15829/1728-8800-2023-3551.
50. Kim OT, Drapkina OM. Obesity epidemic through the prism of evolutionary processes. Cardiovascular Therapy and Prevention. 2022;21(1):3109. (In Russ.) doi:10.15829/1728-8800-2022-3109.
51. Batsis JA. Obesity in the Older Adult: Special Issue. J Nutr Gerontol Geriatr. 2019;38(1):1-5. doi:10.1080/21551197.2018.1564197.
Supplementary files
What is already known about the subject?
- The progressive increase in the prevalence of obesity in the world, along with the trend towards an aging population, determine the socio-economic significance of the problem of sarcopenic obesity.
- Sarcopenic obesity can have an adverse effect on the course and prognosis of non-communicable diseases.
- The combination of excess adipose tissue with a decrease in skeletal muscle mass in sarcopenic obesity causes the low information content of traditional diagnostic tools for overweight and obesity, such as waist circumference and body mass index.
What might this study add?
- Following the described algorithm for diagnosing sarcopenic obesity will improve its detection in clinical practice.
Review
For citations:
Berns S.A., Sheptulina A.F., Mamutova E.M., Kiselev A.R., Drapkina O.M. Sarcopenic obesity: epidemiology, pathogenesis and diagnostic criteria. Cardiovascular Therapy and Prevention. 2023;22(6):3576. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3576. EDN: OWOAYO
Views:
133161
Email this article 
